The phase 3 clinical trial is a prospective, double-blind, randomized multicenter study in the United States. The trial includes placebo and midazolam controls.
Patient recruitment for the study is expected to reach completion in 2016.
More articles on gastroenterology:
Consumerism is taking healthcare by storm: How is GI affected?
3 GI physicians making headlines – June 5, 2015
EndoChoice IPO update: Common stock price set at $15 per share
